

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	2478944
<b>Application Number:</b>	10551869
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	2039
<b>Title of Invention:</b>	4-(2-Phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridine derivatives as serotonin reuptake inhibitors
<b>First Named Inventor/Applicant Name:</b>	Ask Puschl
<b>Customer Number:</b>	45821
<b>Filer:</b>	Margaret M. Buck/Kathleen Andree-Cuneo
<b>Filer Authorized By:</b>	Margaret M. Buck
<b>Attorney Docket Number:</b>	433-US-PCT
<b>Receipt Date:</b>	16-NOV-2007
<b>Filing Date:</b>	31-OCT-2006
<b>Time Stamp:</b>	15:17:46
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement Letter	SIDS_As_Filed.pdf	417453 <small>ef7eb94c7329857052e8a8ea0a50c029 b625942</small>	no	2

**Warnings:**

**Information:**

2	Information Disclosure Statement (IDS) Filed	sb0008a_fill_p1_AS_FILED.pdf	323496 8091231b95c1e89a560b7e72193df ccc48c	no	1
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
3	Information Disclosure Statement (IDS) Filed	sb0008b_fill_p2.pdf	502026 2ba0f04d309961e4636744d54eac9d339 ccc4855	no	1
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
4	Information Disclosure Statement (IDS) Filed	sb0008b_fill_p3.pdf	419944 0132f8ba395053d40d93a98bdc96c05 04519e	no	1
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
5	Foreign Reference	WO99017777A1.pdf	6563359 50d58551b3d49515d11392073bc2904 706154f	no	202
<b>Warnings:</b>					
<b>Information:</b>					
6	Foreign Reference	WO0050380_cited_asPCT-I B00-00108.pdf	2323399 5065597e3cd436de1763d3ef48c9acds 32708f	no	60
<b>Warnings:</b>					
<b>Information:</b>					
7	Foreign Reference	WO04085385A2.pdf	3599511 3c214dfe1521e511c0d53e1f83a17375 b2dc678e	no	87
<b>Warnings:</b>					
<b>Information:</b>					
8	Foreign Reference	WO05000309A2.pdf	4378824 eb14dce428054299191122579ed5a10 2b8c29ff	no	96
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Buckle_et_al_JChemSoc_Pe rkin_Trans_1985.pdf	322024 aab0f0ecode13461c8c30674610c0d aa161e7	no	4
<b>Warnings:</b>					
<b>Information:</b>					

10	NPL Documents	Clayden_J_et_al_Tetrahedron_Org_Chem_Series_2002.pdf	1917091 24f18342143e24013118b4bdc0c14d0e7d42b6056	no	21
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	Dabrowski_et_al_Tetrahedron_2005.pdf	507799 b3ac208374ad2bc83de117e97ec5624d357009	no	6
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Hurd_et_al_JAmerChemSoc_1940.pdf	588738 2bd43ce55cd67e4d3599332ac3a30d4ac489f0	no	11
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Klint_et_al_Drug_Discov_To_day_2004.pdf	763682 cc4c27079eaf8fb0-4c4edd135a5e0aa5e9494	no	6
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	Kunz_Renaissance_Synlett_2003.pdf	889675 01711d485b2c13230e56662352119643c385a330	no	12
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	March_J_et_al_Adv_Org_Chem_1985.pdf	1409737 d29e66-aa8777a6c0d559b7d735e18302006e1c	no	9
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	Sakamuri_S_et_al_BioorgMedChemLett_2001.pdf	414991 ba6d33eed0c344a1bc13d45261a2020ae8bcb0b	no	6
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	Milan_MJ_2003_As_Filed.pdf	3383487 50c96979a32bdcd778c5056eab63ecab012c3a62	no	162
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	Parham_et_al_JOrgChem_1976_AS_FILED.pdf	2854990 951eb3da1f7b67bb00da5e02074312b90c906d	no	5
<b>Warnings:</b>					
<b>Information:</b>					

19	NPL Documents	Sato_etal_Nauyn-Schem_Arch_Pharmacol_2000.pdf	649265 2a800db0781f24c32eca67b710320def07b7eadd	no	7
<b>Warnings:</b>					
<b>Information:</b>					
20	NPL Documents	Siemens_P_etal_Angw_Chem_Int_Ed_2000.pdf	2742728 a23f95b2b3a0ca327b051f5dcf3b3642b16e5d56f	no	26
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	Silverman_RB_The_Org_Chem_of_Drug_Designand_Drug_action_1992.pdf	1445048 e66b099a3d915121cc29c485cd4720b077e205a40	no	3
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	Tamiz_AP_etal_JMedChem_2000.pdf	919856 5a1a370c180d5d9baf210f665b54443ac7e34ae	no	8
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	Wang_S_etal_JMedChem2000.pdf	1151606 1012999a3d915121cc29c485cd4720b077e205a40	no	10
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			38488729		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

#### New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

#### National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

#### New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.